Basilea Completes Recruitment for Phase III AntiFungal Trial
Basilea Pharmaceutica AG, of Basel, Switzerland, completed recruiting patients for a Phase III pivotal trial of its antifungal agent, isavuconazole. With partner Astellas Pharma Inc., Basilea is studying safety and efficacy of once-daily isavuconazole compared to twice-daily voriconazole for up to 84 days of treatment in infections caused by Aspergillus or other filamentous fungi.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST